Business
Bolt is an immuno-oncology company using myeloid biology and its Boltbody ISAC platform to develop cancer therapies.
Bolt Biotherapeutics had flat FY2025 collaboration revenue, lower burn, insider micro-purchases, and an Altman distress screen.
The read at a glance✓ Audited against SEC data
- Business mix — Immuno-oncology ISAC platformNote
- Revenue — $7.7M, flatNote
- FCF — -$39.9MWatch
- Loss — Net loss narrowed 47.1%OK
- Equity — $26.5M, -53.7%Watch
- Insiders — $1.2K purchases / 0 salesNote
- Accounting — Altman distress; Beneish/EQ unavailableWatch
Leadership changes
From Bolt Biotherapeutics, Inc.'s own filings, the day they're filed.
- Mahendra Shah · Directors · departureeff. 2024-12-31
- James Healy · Directors · departureeff. 2024-09-03
- Frank D. Lee · Director · departureeff. 2024-09-03
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Bolt Biotherapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.